Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06134401

Nebulised Hypertonic Saline to Decrease Respiratory Exacerbations in Neuromuscular Disease or Neurodisability

Research Aim: This study investigates whether a 12-month treatment with hypertonic saline (salty water) can reduce antibiotic use in individuals with neuromuscular disease or cerebral palsy who frequently experience chest infections due to difficulty clearing mucus from their airways.

Methodology: Participants will be randomly assigned to receive nebulised hypertonic saline (7% salt in water) or normal saline (0.9% salt in water). The study is open-label as both participants and researchers are aware of the treatment, necessary due to the differing tastes of the solutions. Two centers, Royal Brompton Hospital in London and Queens Medical Centre in Nottingham, will conduct the research.

Before starting the treatment, participants will undergo various assessments, including questionnaires to measure quality of life and treatment satisfaction, sputum/throat swab collection, lung clearance index, forced oscillation technique, electrical impedance tomography, and lung ultrasound. Once these assessments are completed, participants will take the assigned treatment at home, administered twice daily for 12 months, with monthly follow-ups regarding difficulties and chest infections. After 12 months, the treatment will cease, and participants will repeat the assessments.

Significance: This research will provide valuable insights into the efficacy of nebulised hypertonic saline for individuals with neuromuscular disease or cerebral palsy, potentially aiding both patients and doctors in making informed treatment decisions.

Dissemination: The study's findings will be shared through publication in scientific journals and presentation at conferences.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

5 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Royal Brompton Hospital, London, United Kingdom

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of NMD or neurodisablity by a physician independent of the study, on standard criteria.
  • Age 5 years and above, including adults.
  • Must be able to tolerate nebulised 6% hypertonic saline.
  • Must have a history of at least one respiratory exacerbation requiring antibiotic treatment with or without the need for hospitalisation in the 12 months prior to recruitment.

Exclusion criteria

  • Patients with additional diagnosis, for example, CF, but those with aspiration and/or bronchiectasis secondary to respiratory complications of NMD will be included.
  • Patients who are already prescribed daily HS in any concentration (i.e, 3%, 5%, 6%, 7%) will be excluded, but those who are on daily NS or have HS prescribed as part of their escalation plan (i.e., PRN) will be included.

Treatment and study plan

Saline

Device

nebulised

Primary outcomes

  1. Course of antibiotics for respiratory infections

    Time frame: from baseline to week 52

    Full courses of antibiotics as prescribed for respiratory infections, both oral and intravenous, (excluding prophylactic antibiotic prescriptions). 1 course of antibiotic would be the full treatment for one event of respiratory infection, irrespective of the number of days that the course was prescribed for.

Secondary outcomes

  1. Lung clearance index

    Time frame: at baseline before and within 2 hours after drug response assessment, and at week 52.

    measured by multiple breath washout

  2. Forced oscillation technique

    Time frame: at baseline before and within 2 hours after drug response assessment, and at week 52.

    Respiratory resistance (Rrs)

  3. Forced oscillation technique

    Time frame: at baseline before and within 2 hours after drug response assessment, and at week 52.

    Respiratory reactance (Xrs).

  4. Lung ultrasound

    Time frame: at baseline before and within 2 hours after drug response assessment, and at week 52.

    Global Lung ultrasound score. The global lung ultrasound score (LUS) quantifies lung aeration by translating lung ultrasound patterns into a numerical score across 12 lung regions (six areas on each side of the chest: two ventral regions, two lateral regions, and two posterolateral regions) and summing the results. The aeration pattern observed in each region is scored from 0 to 3 as follows: 0 = A pattern with ≤2 B lines; 1 = >2 separated B lines that cover ≤50% of the pleural line; 2 = B lines that cover >50% of the pleural line; or 3 = lung consolidation. In theory, the global LUS score can range from 0 (normal aeration in all regions) to 36 (severe abnormal aeration in all regions).

  5. Electrical Impedance Tomography

    Time frame: at baseline before and within 2 hours after drug response assessment, and at week 52.

    Electrical impedance tomography (EIT)-based global inhomogeneity index (quantification of homogeneity of the tidal volume distribution). The image matrix in EIT consists of 32 × 32 pixels. Global inhomogeneity (GI) is calculated as the sum of the absolute differences between the median value of tidal variation and every single pixel value, divided by the sum of all impedance values, to normalise the calculated values.The smaller the GI, the more homogeneous the tidal volume is distributed within the ventilated area. A GI of zero represents a perfectly homogeneous distribution of ventilation.

  6. Airway inflammation

    Time frame: baseline and at week 52

    Levels of IL-8 in sputum or throat swab.

  7. Airway inflammation

    Time frame: baseline and at week 52

    Levels of IL-6 in sputum or throat swab.

  8. Airway inflammation

    Time frame: baseline and at week 52

    Levels of TNF-a in sputum or throat swab.

  9. Airway inflammation

    Time frame: baseline and at week 52

    Levels of IL-1b in sputum or throat swab.

  10. Bacterial diversity

    Time frame: baseline and at week 52

    Operational taxonomic unit (OTU) Richness, defined as count of different species/OTUs.

  11. Bacterial diversity

    Time frame: baseline and at week 52

    Pielou's eveness index. Pielou's evenness is an index that measures diversity along with species richness.

  12. Bacterial diversity

    Time frame: baseline and at week 52

    Shannon diversity index. The index takes into account the number of species living in a habitat (richness) and their relative abundance (evenness).

  13. Bacterial diversity

    Time frame: baseline and at week 52

    Bray-Curtis dissimilarity index. Examines the abundances of microbes that are shared between two samples, and the number of microbes found in each.

  14. Ease of airway clearance

    Time frame: Once monthly for 52 weeks.

    0-10 Visual analogue scale, where 0 is most easy, and 10 is most difficult.

  15. Health-related quality of life

    Time frame: At baseline and at week 51.

    Pediatric Quality of Life Inventory (PedsQL)™. 0-100 scale, where higher scores indicate better HRQOL (Health-Related Quality of Life).

  16. Patient and main carer treatment satisfaction

    Time frame: weeks 12, 26, 39 and 51

    Treatment Satisfaction Questionnaire for Medication (TSQM Version 1.4). Scores range from 0 to 100, with higher scores indicating higher satisfaction.

  17. Family impact

    Time frame: Baseline and at week 51.

    PedsQL™ Family Impact Module. The scale has five Likert response options, 'never', 'almost never', 'sometimes', 'often' and 'almost always' (corresponding to scores of 100, 75, 50, 25 and 0). Regarding the interpretation of the scale, higher scores indicate better functioning (less negative impact).

  18. Health economics

    Time frame: baseline, week 26 and week 51.

    Quality-adjusted life years

Other outcomes

  1. Recruitment rate

    Time frame: 1 year

    Number of participants recruited per centre per month.

  2. Consent rate

    Time frame: 1 year

    Percentage of eligible participants who consented and were randomised.

  3. Retention rate

    Time frame: 1 year

    Percentage of randomised participants retained with valid primary outcome data.

  4. Adherence

    Time frame: 52 weeks

    Mean percentage of adherence calculated from returned ampoules count

  5. Adherence

    Time frame: 52 weeks

    Pick-up rate as the percentage of picked up prescriptions from total prescribed doses

  6. Adherence

    Time frame: 52 weeks

    The Medication Adherence Report Scale (MARS) Score, where each of the 5 items are summed to give a scale score ranging from 5 to 25, where higher scores indicate higher levels of reported adherence.

  7. Compliance with monthly follow-up

    Time frame: 52 weeks

    Percentage of compliance with completion of monthly questionnaires.

  8. Success rates of outcome measures

    Time frame: 1 year

    Percentage of participants who provided a sputum sample or throat swab

  9. Success rates of outcome measures

    Time frame: 1 year

    Percentage of participants who completed acceptable measurements of Lung clearance index

  10. Success rates of outcome measures

    Time frame: 1 year

    Percentage of participants who completed acceptable measurements of Forced oscillation technique

  11. Success rates of outcome measures

    Time frame: 1 year

    Percentage of participants who completed acceptable measurements of Lung ulstrasound

  12. Success rates of outcome measures

    Time frame: 1 year

    Percentage of participants who completed acceptable measurements of Electrical impedance tomography

  13. Time required to complete outcome measures

    Time frame: 2 hours

    Time in minutes to complete acceptable measurements of Lung clearance index

  14. Time required to complete outcome measures

    Time frame: 2 hours

    Time in minutes to complete acceptable measurements of forced oscillation technique

  15. Inter-rater reliability of Lung ultrasound analysis

    Time frame: 1 year

    Degree of agreement among independent observers using Cohen Kappa. Cohen suggested the Kappa result be interpreted as follows: values ≤ 0 as indicating no agreement and 0.01-0.20 as none to slight, 0.21-0.40 as fair, 0.41- 0.60 as moderate, 0.61-0.80 as substantial, and 0.81-1.00 as almost perfect agreement.

  16. Inter-rater reliability of Electrical impedance tomography analysis

    Time frame: 1 year

    Degree of agreement among independent observers using Cohen Kappa. Cohen suggested the Kappa result be interpreted as follows: values ≤ 0 as indicating no agreement and 0.01-0.20 as none to slight, 0.21-0.40 as fair, 0.41- 0.60 as moderate, 0.61-0.80 as substantial, and 0.81-1.00 as almost perfect agreement.

Study contacts

Contact information is provided by the study sponsor or research team.

Natalia G Galaz Souza

CONTACT

[email protected]

0787131892

Sponsors and collaborators

Lead sponsor

Imperial College London

Other

Collaborators

  • Nottingham University Hospitals NHS Trust
  • Pari Pharma GmbH
  • Royal Brompton & Harefield NHS Foundation Trust

Registry information

Official study title

Effectiveness of Nebulised Hypertonic Saline to Decrease Respiratory Exacerbations in People With Neuromuscular Disease or Neurodisability: a Phase 2 Open Label Pilot Study

Acronym: SPICE-UP

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Nov 18, 2023
Registry last updated
Oct 15, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.